Etzer Darout
Stock Analyst at Barclays
(4.94)
# 164
Out of 5,060 analysts
542
Total ratings
55.4%
Success rate
28.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintained: Buy | $30 | $9.96 | +201.20% | 13 | Oct 19, 2026 | |
| INCY Incyte | Reiterated: Buy | $139 | $113.07 | +22.93% | 18 | Oct 13, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $15 → $18 | $13.62 | +32.16% | 15 | Oct 13, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $271 | $210.23 | +28.91% | 9 | Oct 13, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $74 → $68 | $18.48 | +267.97% | 13 | Oct 13, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $180 | $128.75 | +39.81% | 13 | Oct 13, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $37 | $12.90 | +186.82% | 16 | Oct 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $65 | $34.46 | +88.62% | 8 | Oct 13, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Hold | $58 | $39.90 | +45.36% | 22 | Oct 9, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $78 | $37.32 | +109.00% | 2 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $20 | $14.63 | +36.71% | 14 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $148 | $88.13 | +67.93% | 12 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $46.61 | +60.91% | 14 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $27.53 | +92.52% | 9 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $71.93 | +122.44% | 9 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 → $145 | $69.27 | +109.33% | 10 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $35 | $22.85 | +53.17% | 33 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.08 | +208.37% | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $407 → $415 | $369.06 | +12.45% | 10 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $3 | $1.01 | +197.03% | 10 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.25 | +84.62% | 34 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.77 | +153.16% | 30 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.53 | +193.81% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.28 | +601.75% | 31 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $14 | $16.51 | -15.20% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $30 | $16.28 | +84.28% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $49 | $62.23 | -21.26% | 34 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.97 | +186.94% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $119 | $104.78 | +13.57% | 5 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.94 | n/a | 1 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $143 | $87.71 | n/a | 10 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.64 | n/a | 10 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.79 | n/a | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.86 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $37.00 | n/a | 11 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.42 | n/a | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $150.62 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.52 | n/a | 4 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $0.4799 | n/a | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $37 | $80.18 | n/a | 2 | Sep 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $0.000001 | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $0.3693 | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $25 | $7.57 | n/a | 2 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $48 | $2.32 | n/a | 2 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €23.14 → €26.70 | €2.74 | n/a | 2 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $162 | $231.83 | n/a | 1 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $25.03 | n/a | 4 | Jul 14, 2020 |
Vir Biotechnology
Oct 19, 2026
Maintained: Buy
Price Target: $30
Current: $9.96
Upside: +201.20%
Incyte
Oct 13, 2026
Reiterated: Buy
Price Target: $139
Current: $113.07
Upside: +22.93%
Iovance Biotherapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $15 → $18
Current: $13.62
Upside: +32.16%
Jazz Pharmaceuticals
Oct 13, 2026
Reiterated: Buy
Price Target: $271
Current: $210.23
Upside: +28.91%
Legend Biotech
Oct 13, 2026
Reiterated: Buy
Price Target: $74 → $68
Current: $18.48
Upside: +267.97%
Protagonist Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $180
Current: $128.75
Upside: +39.81%
Syndax Pharmaceuticals
Oct 13, 2026
Reiterated: Buy
Price Target: $37
Current: $12.90
Upside: +186.82%
First Tracks Biotherapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $65
Current: $34.46
Upside: +88.62%
Scholar Rock Holding
Oct 9, 2026
Reiterated: Hold
Price Target: $58
Current: $39.90
Upside: +45.36%
Enliven Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: $78
Current: $37.32
Upside: +109.00%
Oct 1, 2026
Reiterated: Hold
Price Target: $18 → $20
Current: $14.63
Upside: +36.71%
Sep 22, 2026
Reiterated: Buy
Price Target: $148
Current: $88.13
Upside: +67.93%
Sep 22, 2026
Reiterated: Buy
Price Target: $75
Current: $46.61
Upside: +60.91%
Sep 22, 2026
Reiterated: Buy
Price Target: $53
Current: $27.53
Upside: +92.52%
Sep 21, 2026
Reiterated: Buy
Price Target: $160
Current: $71.93
Upside: +122.44%
Sep 11, 2026
Reiterated: Buy
Price Target: $128 → $145
Current: $69.27
Upside: +109.33%
Sep 11, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $22.85
Upside: +53.17%
Sep 10, 2026
Reiterated: Buy
Price Target: $28
Current: $9.08
Upside: +208.37%
Sep 10, 2026
Reiterated: Buy
Price Target: $407 → $415
Current: $369.06
Upside: +12.45%
Aug 20, 2026
Reiterated: Sell
Price Target: $3
Current: $1.01
Upside: +197.03%
Aug 14, 2026
Reiterated: Buy
Price Target: $6
Current: $3.25
Upside: +84.62%
Aug 12, 2026
Reiterated: Buy
Price Target: $7
Current: $2.77
Upside: +153.16%
Aug 7, 2026
Reiterated: Buy
Price Target: $28
Current: $9.53
Upside: +193.81%
Aug 7, 2026
Reiterated: Buy
Price Target: $16
Current: $2.28
Upside: +601.75%
Aug 7, 2026
Reiterated: Sell
Price Target: $14
Current: $16.51
Upside: -15.20%
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $30
Current: $16.28
Upside: +84.28%
Aug 6, 2026
Reiterated: Hold
Price Target: $49
Current: $62.23
Upside: -21.26%
Aug 5, 2026
Reiterated: Buy
Price Target: $20
Current: $6.97
Upside: +186.94%
Dec 8, 2025
Reiterated: Buy
Price Target: $70 → $119
Current: $104.78
Upside: +13.57%
Apr 4, 2025
Reiterated: Buy
Price Target: $9
Current: $2.94
Upside: n/a
Mar 11, 2025
Reiterated: Buy
Price Target: $130 → $143
Current: $87.71
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.64
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.79
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.86
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $37.00
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $24.42
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $150.62
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $7.52
Upside: n/a
Feb 27, 2025
Initiated Coverage: Buy
Price Target: $63
Current: $0.4799
Upside: n/a
Sep 13, 2021
Reiterated: Buy
Price Target: $38 → $37
Current: $80.18
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $7
Current: $0.000001
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $60
Current: $0.3693
Upside: n/a
Mar 17, 2021
Reiterated: Buy
Price Target: $16 → $25
Current: $7.57
Upside: n/a
Mar 11, 2021
Reiterated: Buy
Price Target: $50 → $48
Current: $2.32
Upside: n/a
Mar 5, 2021
Reiterated: Buy
Price Target: €23.14 → €26.70
Current: €2.74
Upside: n/a
Feb 22, 2021
Downgraded: Hold
Price Target: $162
Current: $231.83
Upside: n/a
Jul 14, 2020
Reiterated: Buy
Price Target: $48
Current: $25.03
Upside: n/a